Ginkgo Bioworks Stock News

Presentation and Q&A session scheduled for post-market on Thursday, May 9, 2024 BOSTON , May 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading

Cathie Wood, the founder of Ark Invest, is under intense pressure as most of her ETFs implode. The Ark Innovation Fund (ARKK) ETF has crashed by 72% from its highest level in 2021 while the Ark Genomi

Ginkgo Bioworks (NYSE: DNA ) stock has seen a recent surge in short interest combined with a jump in its share price, fueling speculation that a short squeeze is in the makings for DNA stock. Indeed,

These biotech stocks have missed out on market gains so far, falling in the double digits over the past year. But they are innovators with potential growth catalysts right around the corner.

Analyst price targets for a pair of biotech stocks suggest they can more than double your money over the next 12 months. B. Riley recently lowered expectations for Ginkgo Bioworks, but its new target

The news: Modulus Therapeutics, a Seattle-based cellular therapy company spun out of the Allen Institute of Artificial Intelligence (AI2) Incubator, has sold its cell therapy platform assets to the Bo

Sizing positions correctly is a cornerstone of successful investing, especially when dealing with penny stocks. The unique nature of penny stocks, with their potential for substantial gains, requires

Ginkgo Bioworks is trying to make good on its promises of scaling up. It's adding plenty of new programs, but its revenue is lagging.

Pfizer is a rebound candidate that pays a hefty dividend while you wait. AbbVie has been broadening its product offerings to become more diversified.

Ginkgo Bioworks is aiming to play a key role in drug development. And there's a solid argument for why it could be hugely successful one day.

Ginkgo Bioworks' fourth-quarter results missed Wall Street's revenue and earnings estimates. The company's full-year 2024 revenue guidance was also well below analysts' consensus estimate.

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.

Ginkgo's cell programming process helps businesses launch products and improve existing processes. The company has partnered with many top names in the healthcare industry for this purpose.

Analysts are bullish, on average, regarding both Ginkgo Bioworks and Iovance Biotherapeutics. Ginkgo Bioworks' cost-cutting and manufacturing scaling capabilities are being put to the test.

You can't say Cathie Wood is afraid to make big bets. The investing guru is more than willing to lay it all on the line for stocks she believes in.